


## Tofisopam

## Chemical Properties

CAS No. :	22345-47-7
Formula:	C <sub>22</sub> H <sub>26</sub> N <sub>2</sub> O <sub>4</sub>
Molecular Weight:	382.45
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Tofisopam (Grandaxin) is a 2,3-benzodiazepine compound with anxiolytic activity that can be taken orally.
Targets(IC50)	Others,PDE
In vivo	Tofisopam (30 and 100 mg/kg, po) significantly inhibited the gastric ulceration induced by water-immersion stress in normal rats in a dose-dependent manner. Immobilization-stress loading increased the incidence and average index of gastric ulceration in OB rats, compared with nonstressed rats. Tofisopam (100 mg/kg, po) significantly inhibited the gastric ulceration induced by stress loading in OB rats. Water-immersion stress loading induced a significant increase in intestinal propulsion in rats. This increase was reversed to control levels by tofisopam (100 mg/kg, po). Tofisopam (1.0 mg/kg, iv, or 0.1 mg/kg by intracerebrospinal injection) inhibited the constriction of ear microvessels, the decrease in earlobe temperature, and mydriasis induced by electrical stimulation of the medial hypothalamic area in rabbits[2].

## Solubility Information

Solubility	DMSO: 50 mg/mL (130.74 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.61 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.6147 mL	13.0736 mL	26.1472 mL
5 mM	0.5229 mL	2.6147 mL	5.2294 mL
10 mM	0.2615 mL	1.3074 mL	2.6147 mL
50 mM	0.0523 mL	0.2615 mL	0.5229 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

Hatayama M, Sumida C, Kurajoh M, Shiraishi J, Okazaki H, Shoji T, Koyama H, Tsutsumi Z, Moriwaki Y, Namba M, Yamamoto T. Acute Effects of Oral Tofisopam on Plasma Concentration and Urinary Excretion of Uric Acid and Oxypurinol. *Curr Clin Pharmacol*. 2015 Jan 26. [Epub ahead of print] PubMed PMID: 25619490.

Ramadan NK, Mohamed AO, Fouad RM, Moustafa AA. Different techniques for the determination of tofisopam. *J AOAC Int*. 2014 Jan-Feb;97(1):105-13. PubMed PMID: 24672866.

Abrushanian ÉB, Popov AV. [Pineal hormone melatonin in low doses potentiates psychotropic and chronotropic activity of tofisopam in rats]. *Eksp Klin Farmakol*. 2013;76(4):15-7. Russian. PubMed PMID: 23762983.

Bihel FJ, Justiniano H, Schmitt M, Hellal M, Ibrahim MA, Lugnier C, Bourguignon JJ. New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. *Bioorg Med Chem Lett*. 2011 Nov 1;21(21):6567-72. doi: 10.1016/j.bmcl.2011.08.036. Epub 2011 Aug 12. PubMed PMID: 21920746.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481